Humacyte Inc

HUMANASDAQ · USD
0.45USD+0.05 (+13.33%)
122

Humacyte Inc (HUMA) Covered Calls

Humacyte Inc trades in the Biotechnology industry with an IV Rank of 85.71%, high versus the past year. HUMA's highest covered call setup is the $2.50 strike expiring Jun 17, 2027, sorted by theoretical annualized return. It's 468.18% out of the money with 226 days to expiration, a 479.55% return until expiration, and a 774.49% theoretical annualized return. Across the setups shown, annualized returns run from 170.43% to 774.49% at strikes between $0.50 and $4.50, with 45 to 808 days to expiration, as of Nov 3, 2026.

Read more

Running HUMA covered calls helps you generate income from Humacyte Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best HUMA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If HUMA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling HUMA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given HUMA covered call is worth writing.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.

2027-06-172262.50468.180.050.15211.00479.55774.49-11.36+0.40330.10
2028-01-214444.50922.730.050.20411.00934.09767.89-11.36+0.443510.15
2028-01-214444.00809.090.100.15366.00831.82683.81-22.73+0.452,6270.05
2028-01-214443.50695.450.100.15316.00718.18590.40-22.73+0.456,9270.05
2028-01-214443.00581.820.100.15266.00604.55496.98-22.73+0.462,1740.05
2028-01-214442.50468.180.100.15216.00490.91403.56-22.73+0.465,0040.05
2028-01-214442.00354.550.100.15166.00377.27310.15-22.73+0.474,2260.05
2028-01-214441.50240.910.100.15116.00263.64216.73-22.73+0.492,9330.05
2026-12-18450.5013.640.050.1011.0025.00202.78-11.36+0.521,0480.05
2029-01-198082.00354.550.101.25166.00377.27170.43-22.73+1.001221.15

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank85.71% High
  • Market cap (M$)110
  • 52 weeks high-73.68%
  • 52 weeks low17.65%
  • Analyst recommendationBuy
    1.67
  • Target price$1.62
    261.45% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.49
  • EPS growth next 5 years20.55%

As of Nov 5, 2026